Search

everythinglearnresearchcommunity

for

Search:↓

PRP treatment improves hair growth, and the device used can affect results, with some being more effective.

Minoxidil can help regrow hair in alopecia areata patients.

Chronic Telogen Effluvium may resolve after years and is diagnosed by examining the patient's history and clinical signs, with treatment aimed at underlying causes and possibly minoxidil.

New treatments for severe hair loss often fail, but some patients see hair regrowth with specific therapies, and treatment should be tailored to the individual's situation.

Despite progress in treatment, the exact cause of Alopecia areata is still unknown.

The conclusion is that we need more effective hair loss treatments than the current ones, and these could include new drugs, gene and stem cell therapy, hormones, and scalp cooling, but they all need thorough safety testing.

Some skin disorders might be linked to H. pylori infection, but more research is needed to confirm this.

Thyroid diseases may contribute to autoimmune skin diseases, and more research is needed on their relationship.

Certain genetic markers linked to reproductive potential were identified by their impact on a protein's ability to bind to genes.

Higher DKK-1 levels found in hair loss patients; L-ascorbic acid 2-phosphate, L-threonate, and ginsenoside F2 may help promote hair growth.

FFA in men, often mistaken for other hair loss types, may be more common than thought and needs larger studies for confirmation.

The guide helps clinicians diagnose and manage hair loss, detailing examination techniques and treatments for different types of alopecia.

High prolactin levels might be linked to hair loss in autoimmune thyroid disease, but more research is needed.

Microneedling may improve quality of life and reduce inflammation in frontal fibrosing alopecia.

Patients with thyroid disorders show different symptoms and antibody levels.

Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.

People with alopecia have a higher risk of thyroid cancer.

A woman lost over 80% of her hair due to a condition called telogen effluvium after having COVID-19.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

People with alopecia areata often have higher rates of allergies and autoimmune diseases.

Malondialdehyde-modified DNA may trigger an immune response in alopecia areata patients.

Mild thyroid issues don't affect the metabolism and hormones of women with PCOS.

A woman's hair loss was probably caused by the antifungal drug anidulafungin.

Targeting glycolysis may help treat PCOS by improving insulin sensitivity and ovarian function.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.

Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.

Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.

Venlafaxine can cause hair loss, which stops after discontinuation.

Subclinical hypothyroidism in women with PCOS affects thyroid and hormone interactions but not ovary structure.